TY - JOUR AU - Smeeth, L. AU - Cook, C. AU - Hall, A. J. PY - 2006 DA - 2006// TI - Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001 JO - Ann Rheum Dis VL - 65 UR - https://doi.org/10.1136/ard.2005.046912 DO - 10.1136/ard.2005.046912 ID - Smeeth2006 ER - TY - JOUR AU - Lawrence, R. C. AU - Felson, D. T. AU - Helmick, C. G. AU - Arnold, L. M. AU - Choi, H. AU - Deyo, R. A. AU - Gabriel, S. AU - Hirsch, R. AU - Hochberg, M. C. AU - Hunder, G. G. AU - Jordan, J. M. AU - Katz, J. N. AU - Kremers, H. M. AU - Wolfe, F. PY - 2008 DA - 2008// TI - Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II JO - Arthritis Rheumatism VL - 58 UR - https://doi.org/10.1002/art.23176 DO - 10.1002/art.23176 ID - Lawrence2008 ER - TY - STD TI - Gonzalez-Gay MA, Castaneda S. Llorca J. Giant cell arteritis: visual loss is our major concern. J Rheumatol. 2016;43(8):1458–61. https://doi.org/10.3899/jrheum.160466. ID - ref3 ER - TY - JOUR AU - Hellmich, B. AU - Agueda, A. AU - Monti, S. AU - Buttgereit, F. AU - de Boysson, H. AU - Brouwer, E. AU - Cassie, R. AU - Cid, M. C. AU - Dasgupta, B. AU - Dejaco, C. AU - Hatemi, G. AU - Hollinger, N. AU - Mahr, A. AU - Mollan, S. P. AU - Mukhtyar, C. AU - Ponte, C. AU - Salvarani, C. AU - Sivakumar, R. AU - Tian, X. AU - Tomasson, G. AU - Turesson, C. AU - Schmidt, W. AU - Villiger, P. M. AU - Watts, R. AU - Young, C. AU - Luqmani, R. A. PY - 2020 DA - 2020// TI - 2018 Update of the EULAR recommendations for the management of large vessel vasculitis JO - Ann Rheum Dis VL - 79 UR - https://doi.org/10.1136/annrheumdis-2019-215672 DO - 10.1136/annrheumdis-2019-215672 ID - Hellmich2020 ER - TY - JOUR AU - Soriano, A. AU - Muratore, F. AU - Salvarani, C. PY - 2017 DA - 2017// TI - Visual loss and other cranial ischaemic complications in giant cell arteritis JO - Nat Rev Rheumatol VL - 13 UR - https://doi.org/10.1038/nrrheum.2017.98 DO - 10.1038/nrrheum.2017.98 ID - Soriano2017 ER - TY - JOUR AU - Saleh, M. AU - Turesson, C. AU - Englund, M. AU - Merkel, P. A. AU - Mohammad, A. J. PY - 2016 DA - 2016// TI - Visual complications in patients with biopsy-proven giant cell arteritis: a population-based study JO - J Rheumatol VL - 43 UR - https://doi.org/10.3899/jrheum.151033 DO - 10.3899/jrheum.151033 ID - Saleh2016 ER - TY - JOUR AU - Danesh-Meyer, H. AU - Savino, P. AU - Gamble, G. PY - 2005 DA - 2005// TI - Poor prognosis of visual outcome after visual loss from giant cell arteritis JO - Ophthalmology VL - 112 UR - https://doi.org/10.1016/j.ophtha.2005.01.036 DO - 10.1016/j.ophtha.2005.01.036 ID - Danesh-Meyer2005 ER - TY - JOUR AU - Singh Hayreh, S. AU - Zimmerman, B. PY - 2003 DA - 2003// TI - Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy JO - Ophthalmology VL - 110 UR - https://doi.org/10.1016/S0161-6420(03)00228-8 DO - 10.1016/S0161-6420(03)00228-8 ID - Singh Hayreh2003 ER - TY - JOUR AU - Nesher, G. AU - Berkun, Y. AU - Mates, M. AU - Baras, M. AU - Nesher, R. AU - Rubinow, A. AU - Sonnenblick, M. PY - 2004 DA - 2004// TI - Risk factors for cranial ischemic complications in giant cell arteritis JO - Medicine VL - 83 UR - https://doi.org/10.1097/01.md.0000119761.27564.c9 DO - 10.1097/01.md.0000119761.27564.c9 ID - Nesher2004 ER - TY - JOUR AU - Salvarani, C. AU - Cimino, L. AU - Macchioniet, P. PY - 2005 DA - 2005// TI - Risk FACTORS FOR VISUAL LOSS IN AN ITALIAN POPULATION-BASED COHORT OF PATIENTS WITH GIANT, CELL ARTERITIS JO - Arthritis Rheum VL - 53 UR - https://doi.org/10.1002/art.21075 DO - 10.1002/art.21075 ID - Salvarani2005 ER - TY - STD TI - Pulsatelli L, Boiardi L, Assirelli E, et al. Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study. Clin Exp Rheumatol. 2017;35 Suppl 103(1):102–110. ID - ref11 ER - TY - JOUR AU - Villiger, P. M. AU - Adler, S. AU - Reichenbach, S. PY - 2016 DA - 2016// TI - Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(16)00560-2 DO - 10.1016/S0140-6736(16)00560-2 ID - Villiger2016 ER - TY - JOUR AU - Stone, J. H. AU - Tuckwell, K. AU - Collinson, N. PY - 2017 DA - 2017// TI - Trial of tocilizumab in giant-cell arteritis JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1613849 DO - 10.1056/NEJMoa1613849 ID - Stone2017 ER - TY - STD TI - Foroozan R, Deramo V, Buono L, Savino P et al, Recovery of visual function in patients with biopsy-proven giant cell arteritis, Ophthalmology. 2003;110(3):539–42. ID - ref14 ER - TY - STD TI - Reichenbach S, Adler S, Villiger P et al, Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis. Rheumatology. 2018;57(6):982–86. ID - ref15 ER - TY - JOUR AU - Vodopivec, I. AU - Rizzo, J. F. PY - 2018 DA - 2018// TI - Ophthalmic manifestations of giant cell arteritis JO - Rheumatology (Oxford) VL - 57 UR - https://doi.org/10.1093/rheumatology/kex428 DO - 10.1093/rheumatology/kex428 ID - Vodopivec2018 ER - TY - JOUR AU - Liozon, E. AU - Herrmann, F. AU - Vidal, E. PY - 2001 DA - 2001// TI - Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients JO - Am J Med VL - 111 UR - https://doi.org/10.1016/S0002-9343(01)00770-7 DO - 10.1016/S0002-9343(01)00770-7 ID - Liozon2001 ER - TY - STD TI - Hočevar A, Ješe R, Rotar Ž. Risk factors for severe cranial ischaemic complications in giant cell arteritis. Rheumatology (Oxford). 2020;59(10):2953–59. ID - ref18 ER - TY - STD TI - Seitz L, Wagner F, Christ L et al. No blood for dark-blood: false-negative MRI in a patient with giant cell arteritis and occluded left temporal artery. Clinical vignette in press. Rheumatology. in press. ID - ref19 ER - TY - JOUR AU - Dumont, A. AU - Lecannuet, A. AU - Boysson, H. PY - 2020 DA - 2020// TI - Characteristics and outcomes of patients with ophthalmologic involvement in giant-cell arteritis: a case-control study JO - Semin Arthritis Rheum VL - 50 UR - https://doi.org/10.1016/j.semarthrit.2019.09.008 DO - 10.1016/j.semarthrit.2019.09.008 ID - Dumont2020 ER - TY - STD TI - Chung S, Morcos M, Pollock S. The Veterans Health Administration (VHA) National Database Cohort: Incident Ophthalmic Complications in Giant Cell Arteritis (GCA) Patients with a Negative Temporal Artery Biopsy, Abstract from the 2019 ACR/ARP Annual Meeting. ID - ref21 ER - TY - JOUR AU - Chan, C. K. AU - Paine, M. AU - O’Day, J. PY - 2005 DA - 2005// TI - Predictors of recurrent ischemic optic neuropathy, in giant cell arteritis JO - J Neuroophthalmol VL - 25 UR - https://doi.org/10.1097/00041327-200503000-00004 DO - 10.1097/00041327-200503000-00004 ID - Chan2005 ER - TY - JOUR AU - Foroozan, R. AU - Deramo, V. A. AU - Savino, P. J. PY - 2003 DA - 2003// TI - Recovery of visual function in patients with biopsy-proven giant cell arteritis JO - Ophthalmology VL - 110 UR - https://doi.org/10.1016/S0161-6420(02)01775-X DO - 10.1016/S0161-6420(02)01775-X ID - Foroozan2003 ER - TY - STD TI - Adler S, Reichenbach S, Villiger PM et al. Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology (Oxford). 2019;58(9):1639–43. ID - ref24 ER -